On February 4, 2026, Citigroup raised Bio-Techne’s stock rating to Buy and increased its 12-month price target by 14%, reflecting heightened optimism about the company’s growth trajectory. The upgrade underscores Citigroup’s view that Bio-Techne’s strategic investments in life-science reagents and diagnostics platforms position it favorably against peers such as Thermo Fisher Scientific and Danaher. The firm cited robust demand in large-pharma and Asia markets, as well as the company’s disciplined cost structure, as key drivers of upside potential.

For the quarter ended December 31, 2025, Bio-Techne reported revenue of $295.9 million, flat year-over-year on both a reported and organic basis. GAAP earnings per share rose to $0.24 from $0.22 a year ago, while adjusted EPS improved to $0.46 versus $0.42, topping consensus by 7%. Adjusted operating margin expanded 100 basis points to 31.1%, driven by productivity initiatives and the divestiture of its Exosome Diagnostics business, offsetting a slight revenue dip in core markets.

The Protein Sciences segment generated net sales of $215.1 million, up 2% year-over-year, though organic revenue dipped 1% as unfavorable product mix weighed on results. Operating margin for the segment narrowed to 39.3% from 41.2%. In Diagnostics & Spatial Biology, net sales declined 4% to $81.2 million, yet organic growth was positive at 3%, and operating margin surged to 10.4% from 3.9%, reflecting the benefits of the Exosome Diagnostics divestiture and ongoing cost efficiencies.

Bio-Techne’s Board declared a quarterly cash dividend of $0.08 per share for the fiscal quarter ended December 31, 2025. The dividend will be payable on February 27, 2026, to shareholders of record as of the close of business on February 16, 2026. This marks the company’s continued commitment to returning capital to shareholders while balancing investment in innovation and strategic growth initiatives.